Short answer
Designers of vaccines and therapeutics must prioritize targeting the specific molecular interactions of the SARS-CoV-2 spike protein with ACE2, rather than relying on strategies effective against previous coronaviruses.
- Field
- User-Centred Design
- Source
- Science (2020)
- Method
- Structural Biology / Biophysical Analysis
- Evidence
- Strong effect
The SARS-CoV-2 spike protein's enhanced binding affinity to the ACE2 receptor, compared to SARS-CoV, is a critical factor that must be addressed in the design of effective vaccines and therapeutics. This user-centred design research insight is drawn from a 2020 study published in Science. Using Structural biology / biophysical analysis, researchers explored how this design variable affects real-world outcomes. The key design takeaway: Designers of vaccines and therapeutics must prioritize targeting the specific molecular interactions of the SARS-CoV-2 spike protein with ACE2, rather than relying on strategies effective against previous coronaviruses.
SARS-CoV-2 Spike Protein's Higher ACE2 Affinity Dictates Targeted Therapeutic Design
The SARS-CoV-2 spike protein's enhanced binding affinity to the ACE2 receptor, compared to SARS-CoV, is a critical factor that must be addressed in the design of effective vaccines and therapeutics.
Science · 2020
Key Findings
- 01The 2019-nCoV spike protein has a higher binding affinity to the human ACE2 receptor than the SARS-CoV spike protein.
- 02The predominant conformation of the 2019-nCoV spike trimer has one receptor-binding domain (RBD) in a receptor-accessible 'up' state.
- 03Published SARS-CoV RBD-specific monoclonal antibodies showed limited binding to the 2019-nCoV spike protein, suggesting limited antibody cross-reactivity.
Application
Design takeaway
Designers of vaccines and therapeutics must prioritize targeting the specific molecular interactions of the SARS-CoV-2 spike protein with ACE2, rather than relying on strategies effective against previous coronaviruses.
How to apply
When designing any intervention that targets a specific biological molecule (e.g., a drug, a vaccine, a diagnostic tool), it is essential to understand the precise molecular structure and binding properties of the target to ensure efficacy and specificity.
Project actions
- 01When designing a product that interacts with a biological system, research the specific binding mechanisms and affinities involved.
- 02Consider how changes in molecular structure can significantly impact product effectiveness.
Method & Evidence
Variables
Strengths & Limitations
Strengths
- +Provides high-resolution structural data crucial for rational drug design.
- +Directly compares binding affinities, offering quantitative insights.
Limitations
The complexity of biological systems means that a design based on one specific interaction might have unforeseen consequences or interactions with other biological components.
Reliability & validity
The study's reliability is supported by the use of cryo-EM, a well-established technique for determining protein structures. Validity is enhanced by the direct comparison of binding affinities and the testing of existing antibodies, providing functional evidence for the structural findings.
Think critically
How might the higher binding affinity of SARS-CoV-2 to ACE2 influence the design of diagnostic tests, and what are the potential limitations of such tests?
Design Principles
"Specificity in molecular targeting is crucial for effective therapeutic design."
Understanding the specific molecular interactions and binding affinities of a pathogen's key proteins, like the SARS-CoV-2 spike protein, is fundamental to designing targeted medical interventions. This knowledge directly informs the development of vaccines and antibodies that can effectively block viral entry into host cells, thereby mitigating disease spread and severity.
What This Means for Your Design
The new coronavirus's spike protein is better at sticking to our cells than the old SARS virus's spike protein. This means we need new medicines and vaccines that are specifically designed for this new spike protein, not just ones that worked for SARS.
How to use in your project
- 1.If your project involves designing a medical device or a product that interacts with biological systems, use this to justify why your design targets specific molecular features or physiological responses.
- 2.Use this to explain the need for highly specific testing and validation of your prototype.
Add to My Project
Quick Cite
Paragraph starter
The development of effective medical countermeasures for emerging infectious diseases, such as SARS-CoV-2, necessitates a deep understanding of the pathogen's molecular mechanisms. Research by Wrapp et al. (2020) revealed that the SARS-CoV-2 spike protein exhibits a significantly higher binding affinity to the human ACE2 receptor compared to the SARS-CoV spike protein. This enhanced affinity is a critical factor driving viral infectivity and necessitates that any therapeutic or vaccine design specifically targets these unique binding characteristics, rather than relying on broad-spectrum approaches or designs optimized for previous viral strains.
Source
Science
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
journal · 2020
View sourceQuestions About This Research
- What does the research say about sars-cov-2 spike protein's higher ace2 affinity dictates targeted therapeutic design?
- Designers of vaccines and therapeutics must prioritize targeting the specific molecular interactions of the SARS-CoV-2 spike protein with ACE2, rather than relying on strategies effective against previous coronaviruses. Evidence: Science (2020).
- Why does "SARS-CoV-2 Spike Protein's Higher ACE2 Affinity Dictates Targeted Therapeutic Design" matter for design?
- Understanding the specific molecular interactions and binding affinities of a pathogen's key proteins, like the SARS-CoV-2 spike protein, is fundamental to designing targeted medical interventions. This knowledge directly informs the development of vaccines and antibodies that can effectively block viral entry into host cells, thereby mitigating disease spread and severity.
- How can designers apply this research?
- Designers of vaccines and therapeutics must prioritize targeting the specific molecular interactions of the SARS-CoV-2 spike protein with ACE2, rather than relying on strategies effective against previous coronaviruses.
- What were the main findings?
- The 2019-nCoV spike protein has a higher binding affinity to the human ACE2 receptor than the SARS-CoV spike protein.. The predominant conformation of the 2019-nCoV spike trimer has one receptor-binding domain (RBD) in a receptor-accessible 'up' state.. Published SARS-CoV RBD-specific monoclonal antibodies showed limited binding to the 2019-nCoV spike protein, suggesting limited antibody cross-reactivity.
- What research method was used?
- Structural Biology / Biophysical Analysis.
- How strong is the evidence?
- Evidence strength is rated Strong effect, based on a 2020 journal from Science.
- What should I do differently in my next project?
- When designing any intervention that targets a specific biological molecule (e.g., a drug, a vaccine, a diagnostic tool), it is essential to understand the precise molecular structure and binding properties of the target to ensure efficacy and specificity.
- What are the limitations?
- The study focused on the prefusion conformation of the spike protein; the postfusion conformation might have different binding characteristics. The study did not explore all possible antibody cross-reactivities.